$7900 | Single User
$20500 | Global License
$25800 | Site License

Payer Insights: Hepatitis C
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 26 Sep 2014 | 159 | In Stock
Related Topics: Healthcare , Hepatitis , Pharmacy

Introduction

Introduction


The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives.


Payer Insights: Hepatitis C, based on in-depth interviews with 12 leading healthcare payers in the US, is packed with hard-hitting, candid opinions and advice on how, from their perspective, Pharma can get it right in the future.


Gilead’s commercial success with its ground breaking HCV treatment Solvadi has been matched by the opposition of healthcare payers at the cost.


This report gives insights into what US healthcare payers really think about HCV drug pricing, the growing and frighteningly undefined patient population, limited clinical/outcomes data, poor patient adherence and education - and how can industry positively help and respond.


Scope


Key Takeaways


  • Learn critical lessons when establishing pricing policies and know which approaches will be welcomed by healthcare payers

  • Assess upcoming combination therapy launches from Gilead, AbbVie, Bristol-Myers Squibb and Merck & Co: how do healthcare payers view these developments in clinical and cost terms?

  • Understand current HCV treatment guidelines and know the critical role they play in healthcare payer decisions

  • Accommodate and negate in your product plans the mechanisms by which payers control reimbursement and access to treatment

  • Understand the sometimes conflicting pressures on Medicaid/private HMOs: how could this affect contract negotiations?

  • Gain competitive advantage by providing better more transparent clinical data to support your product – absolutely critical in a world where there is therapy choice

  • Evaluate payer attitudes to price rebates and discounts as well as examining the challenges risk sharing and outcome based pricing could play


  • Puchase Reasons


    Get Answers to Key Questions


  • Which pricing strategies could give you a competitive edge in the crowded HCV market?

  • Diagnostic screening is set to increase: Is it good for patients and bad for economics, and how could it affect you?

  • How could information and education programs utilising trusted and “real world” data be used to better support your clinical and outcomes claims?

  • Which R&D drivers will impact the sector and introduce a new level of treatment options, and when?

  • What practical and commercially beneficial role could industry play in helping patients make sure they take their medicines as directed?

  • Experts Interviewed


  • Chief Medical Officer, Integrated Health Services Organisation

  • Medical Director, Managed Healthcare Company

  • Medical Policy Development Specialist, Managed Care Organisation

  • Senior Clinical Manager, Pharmacy Benefit Manager

  • Pharmacy Director, Community Health Plan

  • Executive Director, Pharmacy Services, Managed Care Organisation

  • Medical Director, Multi-State Healthcare Organisation (covering Medicaid and Medicare lives)

  • Medical Director, Managed Care Organisation

  • Chief Medical Officer, Managed Care Organisation

  • Executive Vice President, Pharmacy Benefit Manager

  • Pharmacy Director, Managed Care Organisation

  • Pharmacy Director, Pharmacy Benefit Manager

  • Features of the report


  • Based on primary and in-depth research with senior managers and planners working daily in public/private managed care organisations across the US

  • Includes candid payer opinion that can help shape your plans and modify behaviour

  • Includes comprehensive background information on the HCV market, which puts the comments from payers into context

  • KOL Quotes

    “Someone needs to look at real world data and state what's really working, what's the most cost-effective treatment, because even for genotype 3 patients, peginterferon and ribavirin are still preferred versus adding Sovaldi, but that hasn't come across [and] everybody's just automatically adding it. You're looking at going from ,000 with a 48 week course to 2,000, 3,000 for a 12 week course. So it's really hard to justify some of this.”


    “What's changed is not solely a function of hepatitis C. It's been influenced by specialty drugs as a whole, and the realisation that if plans didn't have a specialty tier on their drug benefit, they now should. Sovaldi, snuck up on everybody with its pricing… everybody was thinking of Sovaldi as being just a follow on to Incivek and Victrelis. While they were not inexpensive either, Sovaldi took it to another level. Most plans have put in place prior authorisation criteria that allow for its use.”


    “There's a lot of scepticism [and] disbelief or distrust with Gilead and whoever's going to come out next, depending upon what their launch looks like and what their cost is. There's a lot of frustration with the Federal Government in allowing things like this to happen. So I think the next six months are going to be really difficult for the manufacturers. If they come in 20 percent less than what Gilead did and the product is all oral or has a better safety profile, better adherence, better efficacy, I think that they will definitely easily take the market over.”

    Table of Contents
    for Payer Insights: Hepatitis C [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    159 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Cancer Immunotherapy: Payer Insight
    IntroductionImmunotherapies are some of the most promising new weapons in the fight against cancer. ...
    01 Oct 2015 by FirstWord Pharma USD $7,900 More Info
    Biosimilars: US Payer Perspectives
    IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
    01 Apr 2015 by FirstWord Pharma USD $2,195 More Info
    Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives
    IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
    01 Apr 2015 by FirstWord Pharma USD $695 More Info
    Payer Perspectives on Risk Sharing Deals
    IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
    01 Mar 2015 by FirstWord Pharma USD $695 More Info
    Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?
    Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
    25 Feb 2015 by FirstWord Pharma USD $695 More Info
    Biosimilars: European Payer Perspectives
    IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
    06 Jan 2015 by FirstWord Pharma USD $2,195 More Info
    Orphan Drug Market Access: Payer Insights on the Present and Future
    IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
    14 Oct 2014 by FirstWord Pharma USD $695 More Info
    Patient Assistance Programs: Payer and Pharma Perspectives
    IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
    02 Oct 2014 by FirstWord Pharma USD $695 More Info
    Oncology Market Access Europe – Payer and Industry Perspectives
    IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
    03 Jul 2014 by FirstWord Pharma USD $995 More Info
    Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)
    IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
    01 Nov 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Payer Insights: Hepatitis C [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...